Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Preguntas más frecuentes / Tipos de Cáncer
Todd Doyle, MD
Ultima Vez Modificado: 1 de noviembre del 2001
Dear OncoLink "Ask the Experts,"
How long should it take for someone's CEA level to return to normal post surgery for colon cancer?
Thank you,
RH
Todd Doyle, MD, OncoLink Editorial Assistant, responds:
Dear RH:
Thank you very much for your interest and question regarding carcinoembryonic antigen (CEA) levels.
CEA is a glycoprotein that is expressed by normal cells in the gastrointestinal tract, particularly the colon and rectum. It is often over expressed by adenocarcinomas of the colon with higher values reported in better differentiated cancers. Elevated levels are also seen in smokers and in patients with other malignancies including breast, pancreas, stomach, bladder, thyroid, and lung. Its value as a screening modality has not been validated in randomized trials, and has a colon cancer detection rate of less than 4% in the asymptomatic population. However, the level of CEA in patients diagnosed with colorectal cancer seems to be of important prognostic significance and higher values are generally associated with worse outcomes. The normal level for an individual is 3.0 ng/ml and 5.0 ng/ml in smokers.
Using CEA to follow patients after curative resection has also been shown to be of help in predicting recurrence. The sensitivity and specificity of CEA for detecting liver metastases after resection has been reported as 94% and 96%, respectively. More importantly is the issue of whether detecting these metastases earlier can lead to a greater chance of second curative resection and possibly improve survival. A large meta-analysis showed that of patients who underwent regular intensive postoperative evaluations including CEA, physical exams, liver function tests, endoscopic exams, and radiologic exams, there was a greater likelihood of curative resection and an improvement in survival over less stringently followed patients. Specifically, regular postoperative CEA determination detects metastatic disease earlier and was shown to improve survival.
With regard to the rate of normalization of the CEA level after curative resection, there is little published on this subject. However, the CEA clearance half-life is slightly more than five days. Put another way, the value should decline from the preoperative level by approximately one half every five days. This takes into account a number of factors which can differ from patient to patient such as the ability of the body's organs to clear the CEA and the normal rate of production of CEA in a given persons body. So, about three weeks to a month after all the cancer has been irradicated, the level should be nearly as low as it can get. Even so, the time to normalize can vary considerably.
The effect of chemotherapy on the level of CEA should be to lower or stabilize its level. This assumes that the chemotherapeutic agent in use is active in treating the metastatic disease, which is producing the excess CEA. If the level of CEA continues to rise and progression of disease is documented on exam or imaging studies, consideration could be given to a different therapeutic drug or modality.
The following are some references for more information on CEA values:
Dr. Mao talks about complementary and alternative medicine and the importance of being open about their use with cancer caregivers. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)
